Cargando…
A therapeutic cancer vaccine delivers antigens and adjuvants to lymphoid tissues using genetically modified T cells
Therapeutic vaccines that augment T cell responses to tumor antigens have been limited by poor potency in clinical trials. In contrast, the transfer of T cells modified with foreign transgenes frequently induces potent endogenous T cell responses to epitopes in the transgene product, and these respo...
Autores principales: | Veatch, Joshua R., Singhi, Naina, Srivastava, Shivani, Szeto, Julia L., Jesernig, Brenda, Stull, Sylvia M., Fitzgibbon, Matthew, Sarvothama, Megha, Yechan-Gunja, Sushma, James, Scott E., Riddell, Stanley R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363286/ https://www.ncbi.nlm.nih.gov/pubmed/34396986 http://dx.doi.org/10.1172/JCI144195 |
Ejemplares similares
-
Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab
por: Veatch, Joshua R, et al.
Publicado: (2020) -
Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function
por: Leung, Isabel, et al.
Publicado: (2022) -
NEAT: National Epirubicin Adjuvant Trial – toxicity, delivered dose intensity and quality of life
por: Earl, H M, et al.
Publicado: (2008) -
Home-delivered meals as an adjuvant to improve volume overload and clinical outcomes in hemodialysis
por: Perez, Luis M, et al.
Publicado: (2022) -
Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients
por: Leonard, R C F, et al.
Publicado: (2003)